Odronextamab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Marginal Zone B-cell Lymphoma. According to Globaldata, it is involved in 13 clinical trials, of which 11 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Odronextamabs valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Odronextamab is expected to reach an annual total of $324 mn by 2036 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Odronextamab Overview
Odronextamab is under development for the treatment of relapsed/refractory B- cell non-Hodgkin's lymphomas including relapsed/refractory diffuse large B-cell lymphoma, relapsed/refractory follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, Burkitt Lymphoma, primary mediastinal large B-cell lymphoma and acute lymphoblastic leukemia. The therapeutic candidate is administered intravenously. It is an anti-CD20 and anti-CD3 bi-specific monoclonal antibody. It is developed based on VelociSuite technology. It was under development for B-cell Hodgkin's lymphoma.
Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. Regeneron develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick. It also collaborates with strategic partners to develop, manufacture and commercialize its products. The company sells its products to specialty pharmacies and distributors. It operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
The company reported revenues of (US Dollars) US$13,117.2 million for the fiscal year ended December 2023 (FY2023), an increase of 7.8% over FY2022. In FY2023, the companys operating margin was 30.9%, compared to an operating margin of 38.9% in FY2022. In FY2023, the company recorded a net margin of 30.1%, compared to a net margin of 35.6% in FY2022.
The company reported revenues of US$3,145 million for the first quarter ended March 2024, a decrease of 8.4% over the previous quarter.
For a complete picture of Odronextamabs valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.